Tags

Type your tag names separated by a space and hit enter

Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Int J Geriatr Psychiatry 2009; 24(5):532-8IJ

Abstract

OBJECTIVES

The post-hoc analyses reported here evaluate the specific effects of memantine treatment on ADAS-cog single-items or SIB subscales for patients with moderate to severe AD.

METHODS

Data from six multicentre, randomised, placebo-controlled, parallel-group, double-blind, 6-month studies were used as the basis for these post-hoc analyses. All patients with a Mini-Mental State Examination (MMSE) score of less than 20 were included. Analyses of patients with moderate AD (MMSE: 10-19), evaluated with the Alzheimer's disease Assessment Scale (ADAS-cog) and analyses of patients with moderate to severe AD (MMSE: 3-14), evaluated using the Severe Impairment Battery (SIB), were performed separately.

RESULTS

The mean change from baseline showed a significant benefit of memantine treatment on both the ADAS-cog (p < 0.01) and the SIB (p < 0.001) total score at study end. The ADAS-cog single-item analyses showed significant benefits of memantine treatment, compared to placebo, for mean change from baseline for commands (p < 0.001), ideational praxis (p < 0.05), orientation (p < 0.01), comprehension (p < 0.05), and remembering test instructions (p < 0.05) for observed cases (OC). The SIB subscale analyses showed significant benefits of memantine, compared to placebo, for mean change from baseline for language (p < 0.05), memory (p < 0.05), orientation (p < 0.01), praxis (p < 0.001), and visuospatial ability (p < 0.01) for OC.

CONCLUSION

Memantine shows significant benefits on overall cognitive abilities as well as on specific key cognitive domains for patients with moderate to severe AD.

Authors+Show Affiliations

Institute of Gerontology and Geriatrics, University of Perugia, Perugia, Italy. mecocci@unipg.itNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19274640

Citation

Mecocci, Patrizia, et al. "Effects of Memantine On Cognition in Patients With Moderate to Severe Alzheimer's Disease: Post-hoc Analyses of ADAS-cog and SIB Total and Single-item Scores From Six Randomized, Double-blind, Placebo-controlled Studies." International Journal of Geriatric Psychiatry, vol. 24, no. 5, 2009, pp. 532-8.
Mecocci P, Bladström A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry. 2009;24(5):532-8.
Mecocci, P., Bladström, A., & Stender, K. (2009). Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. International Journal of Geriatric Psychiatry, 24(5), pp. 532-8. doi:10.1002/gps.2226.
Mecocci P, Bladström A, Stender K. Effects of Memantine On Cognition in Patients With Moderate to Severe Alzheimer's Disease: Post-hoc Analyses of ADAS-cog and SIB Total and Single-item Scores From Six Randomized, Double-blind, Placebo-controlled Studies. Int J Geriatr Psychiatry. 2009;24(5):532-8. PubMed PMID: 19274640.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. AU - Mecocci,Patrizia, AU - Bladström,Anna, AU - Stender,Karina, PY - 2009/3/11/entrez PY - 2009/3/11/pubmed PY - 2010/5/27/medline SP - 532 EP - 8 JF - International journal of geriatric psychiatry JO - Int J Geriatr Psychiatry VL - 24 IS - 5 N2 - OBJECTIVES: The post-hoc analyses reported here evaluate the specific effects of memantine treatment on ADAS-cog single-items or SIB subscales for patients with moderate to severe AD. METHODS: Data from six multicentre, randomised, placebo-controlled, parallel-group, double-blind, 6-month studies were used as the basis for these post-hoc analyses. All patients with a Mini-Mental State Examination (MMSE) score of less than 20 were included. Analyses of patients with moderate AD (MMSE: 10-19), evaluated with the Alzheimer's disease Assessment Scale (ADAS-cog) and analyses of patients with moderate to severe AD (MMSE: 3-14), evaluated using the Severe Impairment Battery (SIB), were performed separately. RESULTS: The mean change from baseline showed a significant benefit of memantine treatment on both the ADAS-cog (p < 0.01) and the SIB (p < 0.001) total score at study end. The ADAS-cog single-item analyses showed significant benefits of memantine treatment, compared to placebo, for mean change from baseline for commands (p < 0.001), ideational praxis (p < 0.05), orientation (p < 0.01), comprehension (p < 0.05), and remembering test instructions (p < 0.05) for observed cases (OC). The SIB subscale analyses showed significant benefits of memantine, compared to placebo, for mean change from baseline for language (p < 0.05), memory (p < 0.05), orientation (p < 0.01), praxis (p < 0.001), and visuospatial ability (p < 0.01) for OC. CONCLUSION: Memantine shows significant benefits on overall cognitive abilities as well as on specific key cognitive domains for patients with moderate to severe AD. SN - 1099-1166 UR - https://www.unboundmedicine.com/medline/citation/19274640/Effects_of_memantine_on_cognition_in_patients_with_moderate_to_severe_Alzheimer's_disease:_post_hoc_analyses_of_ADAS_cog_and_SIB_total_and_single_item_scores_from_six_randomized_double_blind_placebo_controlled_studies_ L2 - https://doi.org/10.1002/gps.2226 DB - PRIME DP - Unbound Medicine ER -